Do you want to read an article? Please log in or register.
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Genitourinary CancerRadio-Oncology
Related content
Genitourinary CancerRadio-Oncology
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
N Engl J Med.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group
doi: 10.1056/
Genitourinary Cancer
Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer
JAMA.
Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA
doi: 10.1001/jama.2019.20675.
Genitourinary CancerRadio-Oncology
Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data
Cancer.
Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LM, Kim SP, Hoffman KE, Giordano SH, Chapin BF
doi: 10.1002/cncr.30506.
COMMENTED
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study
★ 3
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/S0140-6736(20)30314-7.
COMMENTED
Genitourinary CancerRadio-Oncology
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study
★ 3
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/S0140-6736(20)30314-7.
Genitourinary CancerRadio-Oncology
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Lancet Oncol
Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Zackrisson B, Kjellén E, Franzén L, Widmark A
doi: 10.1016/S1470-2045(20)30581-7
Genitourinary Cancer
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
Lancet Oncol.
Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K
doi: 10.1016/
Lung, Respiratory and Thoracic Cancer
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
Lung Cancer.
Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D
doi: 10.1016/j.lungcan.
RECOMMENDED
Genitourinary Cancer
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Lancet Oncol.
Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, Ramaswamy K, Ivanescu C, Attard G
doi: 10.1016/S1470-2045(18)30898-2.